Sandbox:farnaz: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
This is my sandbox. | |||
== Image reference == | |||
[[File:PulmEdema.PNG|400px|thumb|center|Pulmonary edema <br>Source: Wikimedia commons]] | |||
=== Type 1: === | === Type 1: === | ||
Revision as of 15:25, 8 February 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farnaz Khalighinejad, MD [2]
Overview
This is my sandbox.
Image reference
Source: Wikimedia commons
Type 1:
asdad
Type 2:
The primary therapy for MS may include:[1][2]
- B-interferon
- Teleflunomide
96 patients (174 eyes, 70% females) were included with a mean age at presentation of 30 years
| Cause | Symptom | Diagnosis | Treatment |
|---|---|---|---|
| 1 | |||
| 2 | |||
| 3 |
References
- ↑ Kamm CP, Uitdehaag BM, Polman CH (2014). "Multiple sclerosis: current knowledge and future outlook". Eur Neurol. 72 (3–4): 132–41. doi:10.1159/000360528. PMID 25095894.
- ↑ Schwartz K, Wymbs NF, Huang H, Mealy MA, Pardo CA, Zackowski K; et al. (2017). "Randomized, Placebo-controlled Crossover Study of Dalfampridine Extended-release in Transverse Myelitis". Mult Scler J Exp Transl Clin. 3 (4): 2055217317740145. doi:10.1177/2055217317740145. PMC 5731631. PMID 29270309.